噻托溴铵联合沙美特罗丙酸氟替卡松治疗老年(稳定期)慢性阻塞性肺病的临床效果分析被引量：2

Therapeutic Effect Analysis of Salmeterol/Fluticasone Propionate Combined with Tiotropium Bromide Therapy for Elderly Patients with COPD

在线阅读下载PDF

导出

摘要目的探究噻托溴铵联合沙美特罗丙酸氟替卡松治疗老年(稳定期)慢性阻塞性肺病的临床效果。方法噻托溴铵联合沙美特罗丙酸氟替卡松组(A组)患者给予吸入噻托溴铵干粉剂与沙美特罗丙酸氟替卡松;噻托溴铵组(B组)患者给予吸入噻托溴铵干粉剂;沙美特罗丙酸氟替卡松组(C组)患者给予吸入沙美特罗丙酸氟替卡松,分别在治疗前及治疗后3个月时测定老年(稳定期)慢性阻塞性肺病患者肺功能。结果治疗3个月后,与B、C组相比,A组第1s用力呼气量(FEV1)与用力肺活量(FVC)显著提高,具有统计学意义(<0.05);B组与C组相比用力呼气量(FEV1)与用力肺活量(FVC)差异不显著(>0.05)。结果两种药物联合应用支气管扩张作用更加显著,有利于改善老年(稳定期)慢性阻塞性肺病患者的肺功能,值得临床推广使用。 Objective To explore the therapeutic ef ect of chronic obstructive pulmonary disease(COPD)combination with tiotropium bromide powder for Inhalation(Spiriva)and Salmeterol/Fluticasone.Methods The combined treatment group(group A)was given tiotropium bromide dry powder and Salmeterol/Fluticasone Propionate;tiotropium bromide group(group B)was given tiotropium bromide dry powder;Salmeterol/Fluticasone Propionate group(group C)was given Salmeterol/Fluticasone Propionate.Lung functions were compared in the three groups before and after the treatment three months later.Results Compared with tiotropium bromide group and Salmeterol/Fluticasone Propionate group,the FEV1 and FVC of the combined group improved remarkable(<0.05)on three months later;the improvement between tiotropium bromide group and Salmeterol/Fluticasone Propionate group have no significant dif erences(>0.05).Conclusion Combination of three kinds of medications has stronger bronchiectasis ef ect,which can significantly improve lung function of COPD patients.It is worthy of clinical use.

作者江雨顺 JIANG Yu-shun(Hezhou City People's Hospital,Hezhou 542899,Guangxi,China)

机构地区广西贺州市人民医院

出处《医学信息（医学与计算机应用）》 2014年第19期101-102,共2页 Medical Information

关键词慢性阻塞性肺病噻托溴铵沙美特罗丙酸氟替卡松临床效果分析 Chronic obstructive pulmonary disease Tiotropium bromide Salmeterol/Fluticasone Propionate Therapeutic ef ect analysis

分类号 R5 [医药卫生—内科学]

引文网络
相关文献

参考文献3

1王玥.联合应用噻托溴铵与沙美特罗/氟替卡松治疗中重度COPD稳定期的临床观察[J].中国当代医药,2013,20(3):82-83. 被引量：8
2慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量：8266
3周新,韩伟.COPD预后评价指标的研究[J].中国实用内科杂志：临床前沿版,2006,26(9):1388-1390. 被引量：33

二级参考文献14

1有创-无创序贯机械通气多中心研究协作组.以肺部感染控制窗为切换点行有创与无创序贯机械通气治疗慢性阻塞性肺疾病所致严重呼吸衰竭的随机对照研究[J].中华结核和呼吸杂志,2006,29(1):14-18. 被引量：280
2姚婉贞,常春.支气管舒张剂和吸入糖皮质激素在慢性阻塞性肺疾病中的应用[J].中华结核和呼吸杂志,2007,30(3):223-225. 被引量：99
3GOLD Executive Committee[DB/OL].Guidelines:Global Strategy for Diagnosis,Management,and Prevention of COPD,November 2006[2006-11-18].http://www.goldcopd.com/Guidelineitem.asp? l1 =2-12 = 1&intId =989.
4Celli BR,MacNee W,Committee members.Standard for the diagnosis and treatment of patients with COPD:a summary of the ATS/ERS position paper.Eur Respir J,2004,23:932-946.
5Celli BR,Cote CG,Marin JM,ct al.The body mass index,airflow obstruction,dyspnea and exercise capacity index in chronic obstructive pulmonary disease.N Engl J Med,2004,350:1005-1012.
6冉丕鑫王辰姚婉贞等.我国部分地区慢性阻塞性肺疾病流行病学研究[J].中华结核和呼吸杂志,2007,.
7Sin DD,Man SF,Marciniuk DD. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease[J].American Journal of Respiratory and Critical Care Medicine,2008,(11):1207-1214.doi:10.1164/rccm.200709-1356OC.
8Calverley PM,Anderson JA,Celli B. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease[J].New England Journal of Medicine,2007,(08):775-789.
9Celli BR,MacNee W,ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD:a summary of the ATS/ERS position paper[J].European Respiratory Journal,2004,(06):932-946.
10Brashier B. Tiotropium administered by a pressurized metered dose inhaler(pMDI)and spacer produces a similar bronchodilator response as that administered by a Rotahaler in adult subjects with stable moderate-to-severe COPD[J].Respiratory Medicine,2007,(12):2464-2471.doi:10.1016/j.rmed.2007.07.006.